PL2647637T3 - Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf - Google Patents

Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf

Info

Publication number
PL2647637T3
PL2647637T3 PL11844745T PL11844745T PL2647637T3 PL 2647637 T3 PL2647637 T3 PL 2647637T3 PL 11844745 T PL11844745 T PL 11844745T PL 11844745 T PL11844745 T PL 11844745T PL 2647637 T3 PL2647637 T3 PL 2647637T3
Authority
PL
Poland
Prior art keywords
purinylpyridinylamino
preparation
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
Prior art date
Application number
PL11844745T
Other languages
English (en)
Inventor
Eun Kyong Shim
Nam Doo Kim
Tae Bo Shim
Seung Yong Kim
Original Assignee
Medpacto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medpacto Inc filed Critical Medpacto Inc
Publication of PL2647637T3 publication Critical patent/PL2647637T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL11844745T 2010-12-02 2011-11-25 Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf PL2647637T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20100122047 2010-12-02
PCT/KR2011/009091 WO2012074249A2 (ko) 2010-12-02 2011-11-25 신규한 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 Ｒａｆ키나제의 저해활성을 가지는 약학적 조성물
EP11844745.7A EP2647637B1 (en) 2010-12-02 2011-11-25 Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredient
KR1020110124360A KR101364658B1 (ko) 2010-12-02 2011-11-25 신규한 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 Ｒａｆ키나제의 저해활성을 가지는 약학적 조성물

Publications (1)

Publication Number Publication Date
PL2647637T3 true PL2647637T3 (pl) 2016-06-30

Family

ID=46172371

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11844745T PL2647637T3 (pl) 2010-12-02 2011-11-25 Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf

Country Status (11)

Country Link
US (1) US9216981B2 (pl)
EP (1) EP2647637B1 (pl)
JP (1) JP5689182B2 (pl)
KR (1) KR101364658B1 (pl)
CN (1) CN103339132B (pl)
AU (1) AU2011337461B2 (pl)
CA (1) CA2820550C (pl)
ES (1) ES2562010T3 (pl)
PL (1) PL2647637T3 (pl)
RU (1) RU2550038C2 (pl)
WO (1) WO2012074249A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6031118B2 (ja) * 2011-11-14 2016-11-24 ケンタウルス バイオファーマ カンパニー リミテッド キナーゼを調節する化合物、それらを含む組成物及びその用途
CN103102349B (zh) * 2011-11-14 2017-03-15 北京赛林泰医药技术有限公司 蛋白激酶抑制剂及其组合物和用途
CN103387576A (zh) * 2013-08-09 2013-11-13 中国药科大学 基于嘌呤结构的芳酰胺类Raf激酶抑制剂及其制备方法和用途
CN108602824A (zh) * 2016-01-15 2018-09-28 正大天晴药业集团股份有限公司 一种调节激酶化合物的对甲苯磺酸盐及其结晶
CN109071543B (zh) 2016-02-03 2021-07-16 三进制药株式会社 抑制raf激酶和血管内皮生长因子受体的吡啶衍生物，其制备方法，含有其的药物组合物及其用途
CA2969295A1 (en) * 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
BR112020005455A2 (pt) * 2017-09-20 2020-09-24 Abm Therapeutics Corporation derivados de iminopirimidina cíclica como inibidores de cinase
JP7247557B2 (ja) 2018-11-30 2023-03-29 株式会社リコー 回路基板、回路基板の製造方法、撮像装置

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
MXPA06012613A (es) * 2004-05-07 2007-01-31 Amgen Inc Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
EP1858521A4 (en) * 2005-03-15 2011-07-06 Irm Llc COMPOUNDS AND COMPOSITIONS INHIBITING PROTEINS KINASES
KR20080092412A (ko) 2006-02-06 2008-10-15 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
CA2689092C (en) * 2007-06-07 2013-01-15 Amgen Inc. Raf kinase modulators and methods of use
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP6031118B2 (ja) 2011-11-14 2016-11-24 ケンタウルス バイオファーマ カンパニー リミテッド キナーゼを調節する化合物、それらを含む組成物及びその用途

Also Published As

Publication number Publication date
CA2820550A1 (en) 2012-06-07
CN103339132A (zh) 2013-10-02
CA2820550C (en) 2016-02-23
EP2647637A4 (en) 2013-11-20
JP2013545768A (ja) 2013-12-26
CN103339132B (zh) 2017-02-15
US9216981B2 (en) 2015-12-22
WO2012074249A3 (ko) 2012-08-23
RU2013129993A (ru) 2015-01-10
AU2011337461A1 (en) 2013-07-11
KR20120060744A (ko) 2012-06-12
WO2012074249A2 (ko) 2012-06-07
RU2550038C2 (ru) 2015-05-10
US20130317023A1 (en) 2013-11-28
EP2647637B1 (en) 2016-02-03
JP5689182B2 (ja) 2015-03-25
AU2011337461B2 (en) 2015-04-02
EP2647637A2 (en) 2013-10-09
ES2562010T3 (es) 2016-03-02
KR101364658B1 (ko) 2014-02-19

Similar Documents

Publication Publication Date Title
PL2647637T3 (pl) Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf
WO2011093672A3 (en) Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase
EP2522653A4 (en) BIGUANIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE SUBSTANCE
HK1250714A1 (zh) 雜芳基衍生物或其藥學上可接受的鹽、其製備方法以及包含其作為活性成分的用於預防或治療pi3激酶相關疾病的藥物組合物
EP2917180A4 (en) GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE SUBSTANCE
HUE037742T2 (hu) Szubsztituált azolok, vírusellenes aktív adalék, gyógyszerészeti készítmény, az elõállításukat célzó eljárás és alkalmazásuk
EP2832851A4 (en) IMMORTALIZED STEM CELLS AND MEDICINAL COMPOSITION AND MEDICINAL PREPARATION COMPRISING AN ASSOCIATED PRODUCT AS ACTIVE INGREDIENT
EP2394986A4 (en) DERIVATIVES OF 3 AMINOXALYLAMINOBENZAMIDE AND INSECTICIDE AND MITICIDE AGENTS CONTAINING SAME AS ACTIVE INGREDIENT
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
EP2612914A4 (en) OLIGONUCLEOTIDE, AND THERAPEUTIC AGENT FOR DYSLIPIDEMIA CONTAINING OLIGONUCLEOTIDE AS ACTIVE INGREDIENT
EP2796450A4 (en) 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
EP2654725A4 (en) MICROPARTICLE WITH PHYSIOLOGICALLY ACTIVE PEPTIDE, PROCESS FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
EP2722322A4 (en) 1,3-DI-OXOINDENE DERIVATIVE, ITS OPTICAL ISOMER OR PHARMACEUTICALLY ACCEPTABLE SALT, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ANTIVIRAL ACTIVE INGREDIENT
EP2476420B8 (en) Pharmaceutical composition having antimicrobial and fast-healing activity for external administration, process for preparing same
EP2742950A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING FIBULIN-3 PROTEIN AS AN ACTIVE INGREDIENT FOR INHIBITING GROWTH OF CANCER STEM CELLS
EP2636677A4 (en) CDK-HEMMENDES PYRROLOPYRIMIDINONCARBOXAMID DERIVATIVE OR PHARMACEUTICAL ACCEPTABLE SALT AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEREOF FOR THE PREVENTION OR TREATMENT OF LIVER CELL CARCINOMA
EP2862573A4 (en) COMPOSITION FOR THE TREATMENT OR PROPHYLAXIS OF VASER SPERMABILITY-RELATED DISEASES WITH IMATINIB OR PHARMACEUTICAL ACCEPTABLE SALT AS AN ACTIVE SUBSTANCE
EP2842938A4 (en) NOVEL BETA-ALANINE DERIVATIVES, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT
EP2789604A4 (en) DAZEZE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT AND METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
PT3611158T (pt) Derivado de 1,3-di-oxo-indeno, seu sal farmaceuticamente aceitável ou isómero ótico, seu método de preparação, e composição farmacêutica contendo o mesmo como ingrediente ativo, antiviral
HK1186655A1 (zh) 含有 或其衍生物用作活性成分的抗瘧疾藥物
EP3363799A4 (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
EP2738174A4 (en) NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT